The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study.

"MO: Grant/Research support – BioMarin, Novo Nordisk, Pfizer, Roche, Sanofi, Shire (a Takeda Company); Consultant – BioMarin, Novo Nordisk, Roche, Pfizer, Sanofi, Shire (a Takeda Company); Speaker Bureau – Bayer, BioMarin, Novo Nordisk, Roche, Shire (a Takeda Company). CH has received grants and research support from Shire/Takeda, Bayer, Pfizer, OctaPharma, Novo Nordisk, CSL Behring, and CAF-DCF; and honoraria or consultation fees from Shire/Takeda, Bayer, Pfizer, OctaPharma, Novo Nordisk, Sobi-Biogen, LFB, CAF-DCF, Roche, CSL Behring, Uniqure, and BioMarin. MC has received grants and research support from Bayer, Bioverativ/Sanofi, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Shire/Takeda; and honoraria or consultation fees from Bayer, Bioverativ/Sanofi, CSL Behring, Grifols, LFB, Novo Nordisk, Pfizer, Roche, Shire/Takeda. BG: Grant/research support (CSL Behring, Octapharma); consultancy/speaker bureau (Bayer, Novo Nordisk, Shire, Sobi-Biogen). JG: Employee – Takeda Pharmaceuticals International AG; Shareholder – Takeda. RG: Employee – Takeda Development Center Americas, Inc.; Shareholder – Takeda. LT: Employee – Takeda Pharmaceuticals International AG; Shareholder – Takeda. KK: Grant/research support (Baxalta/Shire, CSL Behring, Novo Nordisk, Pfizer, Sobi uniQure); speaker bureau (Bayer, BioMarin, CSL Behring, Novo Nordisk, Roche, Shire, Sobi, Takeda)."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The AHEAD International study was funded by Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria."

"Trial registration: ClinicalTrials.gov: NCT02078427."